In one paragraphArticle in Contrast media & molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors at 3 institutions in 3 countries.
Andrea TestaKosterlitz Centre for Therapeutics and John Mallard Scottish P.E.T. Centre, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.ORCID 0000-0002-8973-9711 Sergio Dall'AngeloKosterlitz Centre for Therapeutics and John Mallard Scottish P.E.T. Centre, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
Marco MingarelliKosterlitz Centre for Therapeutics and John Mallard Scottish P.E.T. Centre, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
Andrea AugelloKosterlitz Centre for Therapeutics and John Mallard Scottish P.E.T. Centre, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.ORCID 0000-0001-5959-7989 Lutz SchweigerKosterlitz Centre for Therapeutics and John Mallard Scottish P.E.T. Centre, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
Andrew WelchKosterlitz Centre for Therapeutics and John Mallard Scottish P.E.T. Centre, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.ORCID 0000-0002-6350-0673 Charles S ElmoreEarly Chemical Development, Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca R&D, Pepparedsleden 1, 431 50 Mölndal, Sweden.ORCID 0000-0001-7434-8307 Dana DawsonKosterlitz Centre for Therapeutics and John Mallard Scottish P.E.T. Centre, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
Pradeep SharmaSafety and ADME Translational Sciences, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca R&D, Cambridge CB4 0WG, UK.ORCID 0000-0003-3415-8917 Matteo ZandaKosterlitz Centre for Therapeutics and John Mallard Scottish P.E.T. Centre, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.ORCID 0000-0002-8257-5232 University of Aberdeen · GBAstraZeneca (Sweden) · SEAstraZeneca (United Kingdom) · GB
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Indexed as
Drug InteractionsPositron-Emission TomographyAnimalsArteriesBile DuctsFemaleFluorine RadioisotopesFusidic AcidKineticsLiverMembrane Transport ProteinsOrgan SpecificityRats, Sprague-DawleyRifamycinsTissue DistributionTriazolesFluorine RadioisotopesFusidic AcidMembrane Transport ProteinsRifamycinsrifamycin SVTriazoles
Identifiers
PMID30154685
PMCPMC6091370
OpenAlexW2809855206
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390